Jacob Chacko - 11 May 2022 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
11 May 2022
Net transactions value
+$1,288,597
Form type
4
Filing time
13 May 2022, 18:52:01 UTC
Previous filing
25 Mar 2022
Next filing
25 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Purchase $883,569 +304,574 +86% $2.90 657,226 11 May 2022 Direct F1
transaction ORIC Common Stock Purchase $190,467 +69,354 +11% $2.75 726,580 12 May 2022 Direct F2
transaction ORIC Common Stock Purchase $214,561 +76,072 +10% $2.82 802,652 13 May 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average share price of an aggregate total of 304,574 shares purchased in the price range of $2.695 to $2.95 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 Represents the weighted average share price of an aggregate total of 69,354 shares purchased in the price range of $2.70 to $2.77 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3 Represents the weighted average share price of an aggregate total of 76,072 shares purchased in the price range of $2.79 to $2.93 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.